Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etoricoxib + cyanocobalamin is an oral fixed-dose combination of two active pharmaceutical ingredients: etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, and cyanocobalamin, a synthetic form of vitamin B12. Etoricoxib acts by selectively inhibiting the COX-2 enzyme, thereby reducing the production of prostaglandins involved in pain and inflammation. Cyanocobalamin serves as a vitamin B12 replacement to correct or prevent deficiency states. This combination is being developed primarily for the treatment of acute pain, with phase III clinical trials completed in Mexico. The product is not considered a new molecular entity and does not have orphan drug status[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etoricoxib + cyanocobalamin.